Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 372-75-8 | MDL No. : | MFCD00064397 |
Formula : | C6H13N3O3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | RHGKLRLOHDJJDR-BYPYZUCNSA-N |
M.W : | 175.19 | Pubchem ID : | 9750 |
Synonyms : |
N5-Carbamoyl Ornithine;NSC 27425;delta-Ureidonorvaline.;Sitrulline;L-Cytrulline;Citrulline
|
Chemical Name : | H-Cit-OH |
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.67 |
Num. rotatable bonds : | 6 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 4.0 |
Molar Refractivity : | 41.53 |
TPSA : | 118.44 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -9.63 cm/s |
Log Po/w (iLOGP) : | 0.16 |
Log Po/w (XLOGP3) : | -3.19 |
Log Po/w (WLOGP) : | -1.15 |
Log Po/w (MLOGP) : | -3.21 |
Log Po/w (SILICOS-IT) : | -1.74 |
Consensus Log Po/w : | -1.83 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | 1.48 |
Solubility : | 5290.0 mg/ml ; 30.2 mol/l |
Class : | Highly soluble |
Log S (Ali) : | 1.27 |
Solubility : | 3280.0 mg/ml ; 18.7 mol/l |
Class : | Highly soluble |
Log S (SILICOS-IT) : | 0.2 |
Solubility : | 280.0 mg/ml ; 1.6 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.85 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91% | for 46 - 120 h; Enzymatic reaction | EXAMPLES The following Examples have been included to illustrate modes of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill will appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter.Trial manufacturing and pilot production of Citrulline API have been performed. Two trial batches have produced in 15 L fermentors that were followed by two pilot scale batches. The trial batches and pilot productions are explained in more detail below. The purification of the crude material process includes endotoxin reduction and crystallization steps.Two batches of IOL each as well as a scaled-up consignment have been produced following the process of fermentation, extraction and refinement. The first batch began with 1 kg of arginine and resulted in the harvest of 9 L of liquor. The liquor was ultra-refined with 5 K membrane to remove endotoxin and yield 504 g of L-Citruline product. The net weight of L-Citrulline recovered from the stock solution is 685 g.The second batch began with 1 kg of arginine and resulted in the harvest of 9 L of liquor. After extraction and endotoxin removal with 10 K ultra-filter, 160 g of good quality L-Citrulline product was obtained. L-Citrulline recovered from the stock solution weighs 963g.A minor alteration in processing conditions was introduced after the first batch. Initially, the fermentation broth was filtered and the resulting mycel was <n="17"/>used to convert arginine, hence the color of the intermediate product from the first batch appeared paler. A second crystallization process was implemented before obtaining the final product. However, in the second batch, the fermentation broth was used to convert arginine directly. The color of broth was therefore brought into the inversion liquor. This resulted in a solution of darker appearance. At the extraction stage, the number of recrystallization operations was increased. The expected yield was not high due to the high quantity of Citrulline present in the stock solution. Reduction of the concentration of Citrulline in the stock solution should result in improved yield. A scale-up batch was executed with 75 kg arginine. The processing of inversion liquor was extended over three episodes. The crude material yielded can be processed by endotoxin reduction, filtration, drying, and inspection before the final purified product can be collected.The validation of trial batches and the scaled-up pilot batches were commenced in the pilot plant facilities. Validation was performed in two batches using 15 L fermentation. This was followed by the pilot scale production. Results are outlined below in Table I. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | Stage #1: With copper (II) carbonate hydroxide In water for 0.5 h; Reflux Stage #2: With sodium carbonate In water at 0 - 20℃; for 12 h; Stage #3: With thioacetamide In water at 50℃; for 3 h; |
Step 5. A solution of 58-7 (10 g, 68.4 mmol) and Cu(OH)2C03 (15.12 g, 68.4 mmol) in H20 (100 mL) was heated at reflux for 30 min. Solids formed during reflux were removed by filtration while hot. The filtrate was cooled to 0°C and was adjusted to pH 9 by addition of solid Na2C03 (1.0 g). AllocCl (10.8 mL, 102.6 mmol) was added dropwise, while the solution stirred at 0°C. During the addition, the reaction mixture was maintained at pH 9 by the addition of solid Na2C03 (20 g). The reaction mixture was allowed to warm to room temperature and stirred for 12 h. The blue solid product formed during the reaction was collected by filtration in quantitative yield. The solid copper salt of Orn( Alloc) collected above was suspended in H20 (200 mL) and two equivalents of thioacetamide (6.511 g, 86.66 mmol) were added to. The alkaline suspension was stirred at 50°C for 3 h, during which time, the solid slowly dissolved. The solution was then acidified to pH 2 with 2M HC1 and was further boiled for 5 min. The precipitated CuS was removed by filtration. The filtrate was concentrated under vacuum to about 100 mL, at which point the product hydrochloride salt of Orn(Alloc) 58-8 precipitated as a white solid in quantitative yield. |
A450996[ 70796-17-7 ]
(S)-2-amino-5-ureidopentanoic acid 2-hydroxysuccinic acid salt
Reason: Free-Salt
A157241[ 70796-17-7 ]
(S)-2-amino-5-ureidopentanoic acid 2-hydroxysuccinic acid salt
Reason: Free-Salt